loading...| Preferred Name | Cabozantinib S-malate | |
| Synonyms |
|
|
| Definitions |
The s-malate salt form of cabozantinib, an orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Cabozantinib strongly binds to and inhibits several RTKs, which are often overexpressed in a variety of cancer cell types, including hepatocyte growth factor receptor (MET), RET (rearranged during transfection), vascular endothelial growth factor receptor types 1 (VEGFR-1), 2 (VEGFR-2), and 3 (VEGFR-3), mast/stem cell growth factor (KIT), FMS-like tyrosine kinase 3 (FLT-3), TIE-2 (TEK tyrosine kinase, endothelial), tropomyosin-related kinase B (TRKB) and AXL. This may result in an inhibition of both tumor growth and angiogenesis, and eventually lead to tumor regression. |
|
| ID |
http://purl.obolibrary.org/obo/NCIT_C97938 |
|
| Accepted_Therapeutic_Use_For |
advanced renal cell carcinoma (RCC); hepatocellular carcinoma (HCC) |
|
| CAS_Registry |
1140909-48-3 |
|
| Chemical_Formula |
C28H24FN3O5.C4H6O5 |
|
| code |
C97938 |
|
| Contributing_Source |
CTRP FDA |
|
| definition |
The s-malate salt form of cabozantinib, an orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Cabozantinib strongly binds to and inhibits several RTKs, which are often overexpressed in a variety of cancer cell types, including hepatocyte growth factor receptor (MET), RET (rearranged during transfection), vascular endothelial growth factor receptor types 1 (VEGFR-1), 2 (VEGFR-2), and 3 (VEGFR-3), mast/stem cell growth factor (KIT), FMS-like tyrosine kinase 3 (FLT-3), TIE-2 (TEK tyrosine kinase, endothelial), tropomyosin-related kinase B (TRKB) and AXL. This may result in an inhibition of both tumor growth and angiogenesis, and eventually lead to tumor regression. |
|
| Display_Name |
Cabozantinib S-malate |
|
| FDA_UNII_Code |
DR7ST46X58 |
|
| Has_Free_Acid_Or_Base_Form | ||
| Has_Target |
http://purl.obolibrary.org/obo/NCIT_C26203 http://purl.obolibrary.org/obo/NCIT_C17475 http://purl.obolibrary.org/obo/NCIT_C18539 http://purl.obolibrary.org/obo/NCIT_C18488 http://purl.obolibrary.org/obo/NCIT_C17328 http://purl.obolibrary.org/obo/NCIT_C26202 http://purl.obolibrary.org/obo/NCIT_C18186 http://purl.obolibrary.org/obo/NCIT_C17975 |
|
| in_subset |
http://purl.obolibrary.org/obo/NCIT_C63923 http://purl.obolibrary.org/obo/NCIT_C177537 http://purl.obolibrary.org/obo/NCIT_C176424 http://purl.obolibrary.org/obo/NCIT_C116977 http://purl.obolibrary.org/obo/NCIT_C116978 http://purl.obolibrary.org/obo/NCIT_C128784 |
|
| Is_Value_For_GDC_Property | ||
| label |
Cabozantinib S-malate |
|
| Maps_To |
Cabozantinib S-malate |
|
| NCI_Drug_Dictionary_ID |
461103 |
|
| PDQ_Closed_Trial_Search_ID |
461103 |
|
| PDQ_Open_Trial_Search_ID |
461103 |
|
| Preferred_Name |
Cabozantinib S-malate |
|
| prefixIRI |
NCIT:C97938 |
|
| prefLabel |
Cabozantinib S-malate |
|
| Semantic_Type |
Pharmacologic Substance |
|
| UMLS_CUI |
C3468008 |
|
| subClassOf |
http://purl.obolibrary.org/obo/NCIT_C93259 |